2025 Poster Presentations
Preliminary List as of 16 October
Birla Institute of Technology and Science, Pilani
Random Forest Model for the Identification of New Antimalarials: Optimization and Experimental Validation
Centre Leon Berard
Synthesis and Evaluation of PROTAC to Study and Target Protein Kinase CK2
Chemotargets
D3 Platform: A Deep Drug Discovery Approach to Generating Novel Synthetically-Feasible Lead Molecules
Chemotargets
PADME: A New Context-Specific Drug-Likeness Score for Hit-to-Lead Optimization of Physicochemical and ADME Properties
Cresset
Active Learning FEP Using 3D-QSAR for Prioritizing Bioisosteres in Medicinal Chemistry
Daiichi Sankyo Co., Ltd.
Discovery of DS-1093a: An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia
Edelris SAS
Accelerating Molecular Glue Discovery Through Novel Chemical Space and ASMS Screening
eMolecules, Inc.
Trillion-Scale 3D Search Meets Synthesis-Ready Virtual Space: QIMERA Ultra × eMolecules
ETH Zurich
From DEL to Preclinical Models: Discovery and Optimization of a Brain Penetrant MAGL Inhibitor
Goethe University
Discovery of New Covalent Cereblon PROTAC Handles
HTuO Biosciences
AtomForge High-Throughput: Hit Identification Powered by a Sui generis Force Field
ICE Bioscience, Inc.
An Integrated Discovery Platform for STAT6 Therapeutics: From Biochemical Precision to Translational Relevance
Icesi University
QSAR–ML Guided Network Pharmacology for the Identification of Colombian Medicinal Plants With Predicted Anti-Dengue Activity
Institute of Cancer Research
D2B Platform for Rapid PROTAC Synthesis and Testing
Latvian Institute of Organic Synthesis
Bioisosteres of the Hydrolytic Transition State of Aspartic Protease as Plasmepsin V Inhibitors
Latvian Institute of Organic Synthesis
Single Crystal NMR in Spinning Powders: Towards Label-Free Biomolecular Solid-State NMR
Latvian Institute of Organic Synthesis
Targeting Anaerobic Pathways of L-Carnitine and γ-Butyrobetaine Metabolism to Suppress Bacterial Trimethylamine Formation
Merck KGaA
Extract2Chip—Bypassing Protein Purification of Challenging Drug Targets for Streamlined Characterization of Protein-Protein Interactions
Novalix
Identification of a Submicromolar BRD4 PROTAC Degrader from a Moderately Potent DEL Hit: Harnessing the Synergy of DEL and PROTAC Technologies
Optibrium Ltd.
Physical Model Induction with QuanSA™
Pelago Bioscience AB
Investigation of Non-Degraded PROTAC Targets with CETSA
POSTECH
Structure-Based Discovery of DARPin Binders and Their Complexes with Drug Target Proteins
Promega Corporation
De-Risking CRBN-Recruiting Degraders: Characterizing Neosubstrate Degradation Specificity and Selectivity
Promega Corporation
Real-Time Monitoring of Targeted Protein Degradation in Living Cells: Enabling Live-Cell Kinetic Analysis at Every Step
Roche Pharma
Development of a NanoBRET Probe for Compound Profiling of Live Cell MAGL Inhibition: Accelerating Project Progress in Early Stages of a MAGL Inhibitor Program
Sygnature Discovery
Rational Glue Degrader Identification : A Ligase-Agnostic Platform for Molecular Glue Degrader Discovery
Takeda Pharmaceutical Co., Ltd.
Discovery of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 Main Protease Through Computer-Aided Drug Design
Universidad Andres Bello
Rational Design and Computational Evaluation of PROTACs Targeting the Dengue Virus NS3 Protease
Universidad Andres Bello
Rational Design and Experimental Validation of a Modulatory Nanobody Targeting the TRPM4 Ion Channel
University of Bologna
Proteolysis Targeting Chimeras of Casein Kinase 1d (CK1d) for Targeting Circadian Clock Dysfunction in Alzheimer’s Disease (AD)
University of Girona
From Big Data to Smart Fragments: A Knowledge-Guided Approach to Large-Scale Pose Prediction and Library Design
University of Leeds
Plate-Based In Vitro Assays to Evaluate Selectivity of Deubiquitylase (DUB) Inhibitors
University of Leicester
Structural and Chemical Biology Investigations into Class I Histone Deacetylase Ubiquitination and Proteasome Mediated Degradation
University of Lisbon
Development of Highly Specific and Potent Degrader-Antibody Conjugates for Triple-Negative Breast Cancer Treatment: A Step Forward in Precision Cancer Therapy
University of Navarre
An Integrated Platform for the Design, Validation, and Optimization of PROTACs Targeting Epigenetic Regulators
University of Oxford
Fragment-Based Discovery of Novel Starting Points for Rational Inhibitor Design Against Fatty Acid Thioesterase A
University of Stavanger
Machine Learning-Guided Rational Design of Species-Specific SET-M33 Analogs Targeting ESKAPE Pathogens
University of Toronto
Medicinal Chemistry Self-Driving Lab - Accelerating Hit Optimisation with Direct to Biology Approach
University of Tubingen
Linking ATP and Allosteric Sites in EGFR: Structure-Activity Insights into Inactive-Conformation Binding Inhibitors
Vipergen ApS
DELs in Cells – Integral Membrane Screening
WuXi Apptec Co., Ltd.
Accelerating Molecular Glue Discovery with DNA-Encoded Libraries
WuXi Apptec Co., Ltd.
Direct-to-Biology (D2B) Accelerates Hit Identification and Optimization
WuXi Apptec Co., Ltd.
DNA-Encoded Libraries and Display Technologies Empower Early Discovery of Peptide Drugs and Peptide-Based Delivery Tools
WuXi Apptec Co., Ltd.
Streamlined Solutions from Novel E3 Target to Functional PROTAC